|
|
675 Almanor Ave C/O The Parkinson's Institute
Sunnyvale, CA 94085 USA
phone:(408) 737-2734
fax:
|
|
| Symbol |
AMBS |
| Exchange |
OTC BB |
| Founded |
2008 |
| Employees |
3 |
|
|
| www.amarantustherapeutics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| biotechnology company that is develops modifying treatments that address cell death |
|
| Management |
| Martin D. Cleary, Chairman & Chief Executive Officer; John W. Commissiong, PhD, Chief Scientific Officer; Gerald E. Commissiong, Director & Chief Business Officer |
| |
|
|
|
|
|
|
| Recent Results |
| Amarantus Therapeutics is seeking to raise a $1 million investment as a bridge to a $15 million Series A that it will use to advance its lead programs in Parkinson�s and Myocardial Infarction into clinical development. |
| |
|
|
|
|
| Keywords |
| cell death, biotechnology, apoptosis, neurodegenerative diseases, cardiovascular diseases, cardiovascular, neurodegenerative, Parkinson's disease, Myocardial Infaraction |
|
|
|
| Description |
|
Amarantus Therapeutics, formerly known as CNS Protein Therapeutics, is a privately-held biotechnology company that is developing first-in-class disease�modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases, including but not limited to, neurodegenerative and cardiovascular. |
|
| Products / Services |
The Company?s most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of Parkinson?s disease and Myocardial Infarction. Currently incubating at the Parkinson?s Institute.
|
|
| Technology / Differentiation |
Discovered from Amarantus' proprietary Discovery Engine for Secreted Proteins ("DESP"), AMRS001, also known as MANF, is a highly potent, neurotrophic factor currently in pre-clinical development for the treatment of Parkinson?s disease. Coming after other selective neurotrophic factors such as GDNF, Neurturin, NGF, and others, AMRS001?s discovery protocols were designed to identify a molecule that would be highly selective for dopamine producing neurons of the Substantia Nigra.
While the clinical efficacy and benefit of neurotrophic factors has been in doubt, AMRS001 represents a new family of neurotrophic factors with mechanisms of action fundamentally differentiated from its predecessors.
AMRS001 is an endogenous, widely expressed and highly potent growth factor involved in the prevention of apoptosis. This type of cell death is associated with several devastating human diseases as well as injury related disorders. By inhibiting certain pro-apoptotic caspase enzymes , AMRS001 is highly indicated for the treatment of several poorly served medical markets, including Parkinson?s Disease and Myocardial Infarction. |
|
|
| Strategy |
Amarantus? business strategy, is to discover clinically relevant secreted human proteins, each with the potential to address several critically important medical indications, using our Discovery Engine for Secreted Proteins and develop them in order to address significant patient needs.
|
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
